# US 2002/0172692 A1 · Vaccine composition against malaria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0172692 A1
- Document ID: US20020172692A1
- Status: Published application
- Kind: A1
- Application number: 10/024,860
- Filed: 2001-12-18
- Published: 2002-11-21
- Earliest claimed: 1996-08-02
- Assignees: SmithKline Beecham Biologicals s.a.
- Inventors: Joseph Cohen
- Web page: https://patentgrep.com/patent/US20020172692A1

## CPC

- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 33/06: Antimalarials
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/575: {humoral response}
- C12N 2730/10111: Orthohepadnavirus, e.g. hepatitis B virus
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to a vaccine composition useful in the prevention or treatment of malaria comprises a plurality of malaria-derived antigens in combination with an adjuvant which is a preferential stimulator of TH1 cell response.

## Claims

### Claim 1

A vaccine composition for use in the prevention or treatment of malaria, comprising a plurality of malaria-derived antigens in combination with an adjuvant which is a preferential stimulator of TH1 cell response.

### Claim 2 (depends on 1)

A vaccine composition according to claim 1, wherein the adjuvant comprises MPL.

### Claim 3 (depends on 1, 2)

A vaccine composition according to claim 1 or 2, wherein the adjuvant comprises QS21.

### Claim 4

A vaccine composition according to any one of the preceding claims, wherein the adjuvant comprises an oil-in-water emulsion.

### Claim 5

A vaccine composition according to any one of the preceding claims, wherein the malaria antigens are selected from the group consisting of:
a hybrid protein comprising substantially all the C-terminal portion of the CS protein, four or more tandem repeats of the immunodominant region, and the surface antigen from Hepatitis B virus (HBsAg);
the TRAP of a cloned isolate of P. falciparum from Thailand known as T/9/96, and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
the 16kD protein described in International Patent Application No. WO 91/18922, and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
the apical membrane antigen-1 (AMA-1) of P. falciparum or P. vivax, and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
the circumsporozoite protein (csp) of P. falciparum or P. vivax, and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
the MSP-1 of P. falciparum or P. vivax (U.S. Pat. No. 4,837,016), and proteins having at least 80% homology thereto, and immunogenic derivatives including fragments thereof;
other exoerythrocytic stage proteins and immunogenic derivatives including fragments thereof; and
optionally, blood stage proteins and immunogenic derivatives including fragments thereof.

### Claim 6

A vaccine composition according to any one of the preceding claims, for use in therapy.

### Claim 7 (depends on 1, 2, 3, 4, 5)

Use of a vaccine composition according to any one of claims 1 to 5 in the manufacture of a medicament for use in the treatment or prophylaxis of malaria.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A method of treating or preventing malaria, which comprises administering to a patient in need thereof an effective amount of a vaccine composition according to any one of claims 1 to 5.
